Synopsis
Synopsis
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Allegron
2. Apo Nortriptyline
3. Apo-nortriptyline
4. Aventyl
5. Desitriptyline
6. Desmethylamitriptylin
7. Gen Nortriptyline
8. Gen-nortriptyline
9. Hydrochloride, Nortriptyline
10. Norfenazin
11. Nortrilen
12. Nortriptyline
13. Novo Nortriptyline
14. Novo-nortriptyline
15. Nu Nortriptyline
16. Nu-nortriptyline
17. Pamelor
18. Paxtibi
19. Pms Nortriptyline
20. Pms-nortriptyline
21. Ratio Nortriptyline
22. Ratio-nortriptyline
1. 894-71-3
2. Nortriptyline Hcl
3. Pamelor
4. Desmethylamitriptyline Hydrochloride
5. Allegron
6. Acetexa
7. Altilev
8. Nortriptyline (hydrochloride)
9. Nortrilen
10. Aventyl Hydrochloride
11. Sensival
12. Vividyl
13. Aventyl Allegron
14. Ateben Hydrochloride
15. Nortab Hydrochloride
16. Psychostyl
17. Nortriptylin Hydrochloride
18. Lilly 38489
19. Noramitriptyline Hydrochloride
20. Nortriptyline Monohydrochloride
21. Nsc-169453
22. 3-(10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methyl-1-propanamine Hydrochloride
23. Mls000069673
24. 00fn6ih15d
25. N 7048
26. Smr000058486
27. Pamelor Hydrochloride
28. 1-propanamine, 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n-methyl-, Hydrochloride
29. Nortriptylene Hydrochloride
30. Norzepine
31. 3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methylpropan-1-amine Hydrochloride
32. Wln: L C676 By&t&j Bu3m1 &gh
33. Nsc78248
34. Nortriptylinehydrochloride
35. Nsc169453
36. Sr-01000000223
37. Cas-894-71-3
38. Mfcd00058024
39. Unii-00fn6ih15d
40. 5-[3-(methylamino)propylidene]dibenzo[a,5]diene Hydrochloride
41. (2)10,d]cycloheptene-.delta.5.gamma.-propylamine, Hydrochloride
42. 5-[(3-(methylamino)propylidene]-10,d]cycloheptene Hydrochloride
43. 5h-dibenzo[a,.gamma.-propylamine, 10,11-dihydro-n-methyl-, Hydrochloride
44. 5h-dibenzo[a,.gamma.-propylamine, 10-11-dihydro-n-methyl-, Hydrochloride
45. 1-propanamine,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methyl-, Hydrochloride
46. Desitriptyline Hcl
47. 3-(5,6-dihydrodibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-n-methylpropan-1-amine;hydrochloride
48. Prestwick_366
49. Einecs 212-973-0
50. Pamelor (tn)
51. Nsc 78248
52. Nsc 169453
53. Cpd000058486
54. Elf-101 Hydrochloride
55. En-7048 Hydrochloride
56. Nortriptyline Hydrochloride [usan:usp:jan]
57. Opera_id_1915
58. Dsstox_cid_25109
59. Dsstox_rid_80676
60. Dsstox_gsid_45109
61. Schembl41329
62. Mls001077267
63. Mls002222206
64. Mls006010656
65. Chebi:7641
66. Chembl1201156
67. Dtxsid2045109
68. Regid_for_cid_441358
69. Hms1568d10
70. Nortriptyline Hydrochloride- Bio-x
71. Hy-b1417
72. Nortriptyline For System Suitability
73. Tox21_110048
74. Tox21_500868
75. Nsc-78248
76. S3698
77. 5-(3-(methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene Hydrochloride
78. Akos015889095
79. Ccg-212718
80. Cs-4913
81. Ks-1306
82. Lp00868
83. Nc00522
84. 10,11-dihydro-5-(n-methyl-3-aminopropylidene)-5h-dibenzo[a,d]cycloheptene Hydrochloride
85. 5-(3-methylaminopropylidene)-10,11-dihydro-5h-dibenzo(a,d)cycloheptene Hydrochloride
86. Nortriptyline Hydrochloride [mi]
87. Ncgc00014483-01
88. Ncgc00094192-01
89. Ncgc00094192-02
90. Ncgc00261553-01
91. Nortriptyline Hydrochloride [jan]
92. 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine Hydrochloride
93. Bn164160
94. Nortriptyline Hydrochloride [hsdb]
95. Nortriptyline Hydrochloride [usan]
96. Nortriptyline Hydrochloride [mart.]
97. Nortriptyline Hydrochloride [vandf]
98. Nortriptyline Hydrochloride [usp-rs]
99. Nortriptyline Hydrochloride [who-dd]
100. Eu-0100868
101. Ft-0673146
102. Ft-0673147
103. N0957
104. Nortriptyline Hydrochloride (jp17/usp/inn)
105. En300-26665
106. D00816
107. F19641
108. N 7261
109. Nortriptyline Hydrochloride [orange Book]
110. Nortriptyline Hydrochloride [ep Monograph]
111. Nortriptyline Hydrochloride [usp Monograph]
112. Nortriptyline Hydrochloride, >=98% (tlc), Powder
113. Sr-01000000223-2
114. Sr-01000000223-7
115. W-109609
116. Q27231345
117. Nortriptyline Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
118. Nortriptyline Hydrochloride, British Pharmacopoeia (bp) Reference Standard
119. Nortriptyline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
120. 3-(10,11-2h-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methyl-1-propanaminium Chloride
121. 3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methylpropan-1-aminehydrochloride
122. Nortriptyline For System Suitability, European Pharmacopoeia (ep) Reference Standard
123. Nortriptyline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
124. 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-d(sup5,.gamma.)-propylamine Hydrochloride
125. 1001637-77-9
126. 5h-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10-11-dihydro-n-methyl-, Hydrochloride
127. Nortriptyline Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 299.8 g/mol |
---|---|
Molecular Formula | C19H22ClN |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 3 |
Exact Mass | 299.1440774 g/mol |
Monoisotopic Mass | 299.1440774 g/mol |
Topological Polar Surface Area | 12 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 307 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Nortriptyline hydrochloride |
PubMed Health | Nortriptyline (By mouth) |
Drug Classes | Antidepressant |
Drug Label | Nortriptyline hydrochloride is 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-, hydrochloride. The structural formula is represented below:C19H21NHCl M.W. 299.84Nortriptyline Hydrochloride Capsules USP (equivalent to 1... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule; Solution |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base/5ml; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Teva; Pharm Assoc; Taro; Watson Labs; Mylan |
2 of 4 | |
---|---|
Drug Name | Pamelor |
Drug Label | Pamelor (nortriptyline HCl) is 1-propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)-N-methyl-, hydrochloride.The structural formula is as follows:... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Mallinckrodt |
3 of 4 | |
---|---|
Drug Name | Nortriptyline hydrochloride |
PubMed Health | Nortriptyline (By mouth) |
Drug Classes | Antidepressant |
Drug Label | Nortriptyline hydrochloride is 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-, hydrochloride. The structural formula is represented below:C19H21NHCl M.W. 299.84Nortriptyline Hydrochloride Capsules USP (equivalent to 1... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule; Solution |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base/5ml; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Teva; Pharm Assoc; Taro; Watson Labs; Mylan |
4 of 4 | |
---|---|
Drug Name | Pamelor |
Drug Label | Pamelor (nortriptyline HCl) is 1-propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)-N-methyl-, hydrochloride.The structural formula is as follows:... |
Active Ingredient | Nortriptyline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 75mg base; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Mallinckrodt |
Antidepressive Agents, Tricyclic
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
28
PharmaCompass offers a list of Nortriptyline API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nortriptyline manufacturer or Nortriptyline supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nortriptyline manufacturer or Nortriptyline supplier.
PharmaCompass also assists you with knowing the Nortriptyline API Price utilized in the formulation of products. Nortriptyline API Price is not always fixed or binding as the Nortriptyline Price is obtained through a variety of data sources. The Nortriptyline Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 00FN6IH15D manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 00FN6IH15D, including repackagers and relabelers. The FDA regulates 00FN6IH15D manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 00FN6IH15D API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 00FN6IH15D manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 00FN6IH15D supplier is an individual or a company that provides 00FN6IH15D active pharmaceutical ingredient (API) or 00FN6IH15D finished formulations upon request. The 00FN6IH15D suppliers may include 00FN6IH15D API manufacturers, exporters, distributors and traders.
click here to find a list of 00FN6IH15D suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 00FN6IH15D DMF (Drug Master File) is a document detailing the whole manufacturing process of 00FN6IH15D active pharmaceutical ingredient (API) in detail. Different forms of 00FN6IH15D DMFs exist exist since differing nations have different regulations, such as 00FN6IH15D USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 00FN6IH15D DMF submitted to regulatory agencies in the US is known as a USDMF. 00FN6IH15D USDMF includes data on 00FN6IH15D's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 00FN6IH15D USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 00FN6IH15D suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 00FN6IH15D Drug Master File in Japan (00FN6IH15D JDMF) empowers 00FN6IH15D API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 00FN6IH15D JDMF during the approval evaluation for pharmaceutical products. At the time of 00FN6IH15D JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 00FN6IH15D suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 00FN6IH15D Drug Master File in Korea (00FN6IH15D KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 00FN6IH15D. The MFDS reviews the 00FN6IH15D KDMF as part of the drug registration process and uses the information provided in the 00FN6IH15D KDMF to evaluate the safety and efficacy of the drug.
After submitting a 00FN6IH15D KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 00FN6IH15D API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 00FN6IH15D suppliers with KDMF on PharmaCompass.
A 00FN6IH15D CEP of the European Pharmacopoeia monograph is often referred to as a 00FN6IH15D Certificate of Suitability (COS). The purpose of a 00FN6IH15D CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 00FN6IH15D EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 00FN6IH15D to their clients by showing that a 00FN6IH15D CEP has been issued for it. The manufacturer submits a 00FN6IH15D CEP (COS) as part of the market authorization procedure, and it takes on the role of a 00FN6IH15D CEP holder for the record. Additionally, the data presented in the 00FN6IH15D CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 00FN6IH15D DMF.
A 00FN6IH15D CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 00FN6IH15D CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 00FN6IH15D suppliers with CEP (COS) on PharmaCompass.
A 00FN6IH15D written confirmation (00FN6IH15D WC) is an official document issued by a regulatory agency to a 00FN6IH15D manufacturer, verifying that the manufacturing facility of a 00FN6IH15D active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 00FN6IH15D APIs or 00FN6IH15D finished pharmaceutical products to another nation, regulatory agencies frequently require a 00FN6IH15D WC (written confirmation) as part of the regulatory process.
click here to find a list of 00FN6IH15D suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 00FN6IH15D as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 00FN6IH15D API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 00FN6IH15D as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 00FN6IH15D and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 00FN6IH15D NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 00FN6IH15D suppliers with NDC on PharmaCompass.
00FN6IH15D Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 00FN6IH15D GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 00FN6IH15D GMP manufacturer or 00FN6IH15D GMP API supplier for your needs.
A 00FN6IH15D CoA (Certificate of Analysis) is a formal document that attests to 00FN6IH15D's compliance with 00FN6IH15D specifications and serves as a tool for batch-level quality control.
00FN6IH15D CoA mostly includes findings from lab analyses of a specific batch. For each 00FN6IH15D CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
00FN6IH15D may be tested according to a variety of international standards, such as European Pharmacopoeia (00FN6IH15D EP), 00FN6IH15D JP (Japanese Pharmacopeia) and the US Pharmacopoeia (00FN6IH15D USP).